Understanding acute and long-term adverse events following CAR T cell therapy for cancer remains a crucial area of investigation as CAR T cells become more prominent in the clinic. In this issue of Cell, Geraghty et al. investigate the mechanisms underlying cognitive decline in animal models following CAR T cell therapy for hematological, solid, and CNS malignancies.